Placental growth factor

4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMD

Retrieved on: 
Monday, October 23, 2023
FDA, VEGF, CST, AAV, Intravitreal injection, PRISM, AMD, DME, European Medicines Agency, SAE, Diabetic retinopathy, EMA, Safety, Intraocular pressure, Patient, Anti-VEGF, Vaccine, Pharmaceutical industry, Placental growth factor

PRIME designation is granted by the EMA to enhance support for the development of medicines that target an unmet medical need and offers the opportunity to accelerate review of the marketing applications to bring such medicines to patients sooner.

Key Points: 
  • PRIME designation is granted by the EMA to enhance support for the development of medicines that target an unmet medical need and offers the opportunity to accelerate review of the marketing applications to bring such medicines to patients sooner.
  • The designation follows positive interim Phase 1 PRISM clinical data for 4D-150 that demonstrated an encouraging safety, tolerability and clinical activity profile.
  • “We are thrilled that the EMA has awarded PRIME designation to intravitreal 4D-150,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.
  • We are efficiently advancing 4D-150 development for treatment of both wet AMD and DME patients, both of which represent large market opportunities.

4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)

Retrieved on: 
Monday, November 14, 2022
Clinical trial, Principal, Safety, Security (finance), DME, VEGF, Diabetic retinopathy, Eye, PRISM, Partner (business rank), Blood, Webcast, AAV, Retina, Cystic fibrosis, Conference, Paganini Competition, Clinical research, Choroideremia, CNV, Inflammation, M.A, University, AMD, Fabry disease, Choroidal neovascularization, Molecule, R100, Hallucination, Macular degeneration, Therapy, US, Swelling, Severe cognitive impairment, University of Nevada, Reno, Ophthalmology, Injection, Fabry, Edema, Nobel, RNA interference, Bleeding, Tissue, Risk, Conference call, Cardiology, Scar, Patient, Medical device, Pharmaceutical industry, Vaccine, Placental growth factor

4D Molecular Therapeutics will host a conference call today, Monday November 14, 2022 at 8:00 AM E.T.

Key Points: 
  • 4D Molecular Therapeutics will host a conference call today, Monday November 14, 2022 at 8:00 AM E.T.
  • This clinical data on 4D-150 marks an important milestone for 4DMT, said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.
  • We are developing 4D-150 for the treatment of large and sustainable markets in ophthalmology, including wet AMD and diabetic macular edema.
  • I am looking forward to enrolling patients in the randomized Phase 2 expansion stage of this clinical trial.

4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released Monday, November 14, 2022

Retrieved on: 
Thursday, November 10, 2022
Investor, GLOBE, Private Securities Litigation Reform Act, Scar, Hallucination, Infrared spectroscopy correlation table, Risk, U.S. Securities and Exchange Commission, Macular degeneration, Swelling, Choroideremia, Nasdaq, Webcast, Tissue, Blood, Cystic fibrosis, Fabry, Bleeding, Ophthalmology, Therapy, US, Severe cognitive impairment, AMD, Choroidal neovascularization, Safety, RNA interference, VEGF, Molecule, Edema, Retina, Clinical trial, Patient, Security (finance), Cardiology, Percentage, CNV, Fabry disease, Pharmaceutical industry, Vaccine, Placental growth factor

4D Molecular Therapeutics also announced that interim clinical data from cohort 1 of this Phase 1/2 clinical trial will be released at 7:30 am E.T., on Monday, November 14, 2022.

Key Points: 
  • 4D Molecular Therapeutics also announced that interim clinical data from cohort 1 of this Phase 1/2 clinical trial will be released at 7:30 am E.T., on Monday, November 14, 2022.
  • 4D will host a conference call and live webcast on November 14th, 2022, at 8:00 am E.T.
  • 4D Molecular Therapeutics will host a conference call and live webcast on November 14, 2022, at 8:00 am E.T.
  • 4D Molecular Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

2022 Preeclampsia Foundation Vision Grant Awardees Announced

Retrieved on: 
Friday, August 19, 2022
Interview, Mount Sinai Hospital, McMaster University, Hypertension, Oxidative stress, Placental insufficiency, Diagnosis, Obstetrics, Pregnancy, Rivers Foundation (Canada), Board, Classification, Medical genetics, Research, Hope, Visions (Grant Green album), Patient, Review, DNA, Education, Princess Margaret Cancer Centre, University, Pre-eclampsia, Gynaecology, Ageing, Doctor of Philosophy, Awareness, Time-invariant system, Wilson, Snelgrove, Board of directors, Master of Science, Western University, Mother, MD, Placental growth factor, Volunteering, Health, Pharmaceutical industry, Management, Medical imaging, MFM

MELBOURNE, Fla., Aug. 19, 2022 /PRNewswire/ -- The Preeclampsia Foundation and the Preeclampsia Foundation Canada have announced that John Snelgrove, MD, MSc, and Samantha Wilson, PhD, are their 2022 Vision Grant research award recipients respectively.

Key Points: 
  • MELBOURNE, Fla., Aug. 19, 2022 /PRNewswire/ -- The Preeclampsia Foundation and the Preeclampsia Foundation Canada have announced that John Snelgrove, MD, MSc, and Samantha Wilson, PhD, are their 2022 Vision Grant research award recipients respectively.
  • A scientific review committee reviews all Vision Grant applications with a further review by a patient advisory board, who then make a recommendation on the awardees for the year.
  • Dr. Snelgrove's research study entitled "Preeclampsia phenotypes: Reclassifying the hypertensive disorders of pregnancy" will be conducted at Mount Sinai Hospital affiliated with the University of Toronto in Ontario, Canada and funded by the US-based Preeclampsia Foundation.
  • Dr. Wilson's research study entitled "Non-invasively assessing placental aging and oxidative stress as markers for preeclampsia: will be conducted at McMaster University also in Ontario, Canada, and funded by Preeclampsia Foundation Canada.

Two PerkinElmer Tests Added to UK’s Updated NICE Diagnostic Guidance for Suspected Preterm Pre-Eclampsia

Retrieved on: 
Wednesday, July 27, 2022
General Health, Pharmaceutical, Consumer, Hospitals, Genetics, Health Technology, Baby, Maternity, Women, Biotechnology, Medical Supplies, Practice Management, Health, Diagnosis, Food, Xpress, United, Instagram, Twitter, Decision-making, Woman, Government, Solution, Health, Safety, Hospital, NICE, Pre-eclampsia, CE, YouTube, Company, Science, LinkedIn, Reproductive health, TM, ESG, Informatics, Automation, PerkinElmer, Medical device, Facebook, Placental growth factor

NICE guidelines are evidence-based recommendations for health and care in the UK.

Key Points: 
  • NICE guidelines are evidence-based recommendations for health and care in the UK.
  • PerkinElmer also offers the DELFIA Xpress random access platform for prenatal screening, which is used to process tests from both kits.
  • PerkinElmer is a global leader in prenatal and newborn screening , offering a comprehensive portfolio of solutions in both areas.
  • To learn more about the CE marked test kits included in this NICE guidance, along with other solutions for pre-eclampsia screening and management, visit this webpage .

Placenta Growth Factor Pipeline Review, H1 2020: Companies Involved in Therapeutics Development - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 21, 2020
Health, Pharmaceutical, Branches of biology, Growth factors, Angiology, Medical specialties, Placental growth factor, Vascular endothelial growth factor, Endothelium, Platelet-derived growth factor, Vascular endothelial growth factor A

The "Placenta Growth Factor - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Placenta Growth Factor - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This latest report provides comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor).
  • This report also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects.

Polaris Growth Fund Makes Strategic Investment in TransACT Communications

Retrieved on: 
Thursday, March 5, 2020
Software, TransACT, Software as a service, Placental growth factor, Computing, Digital technology

SEATTLE, March 5, 2020 /PRNewswire/ --TransACT Communications, LLC ("TransACT"), a leading SaaS provider of engagement, compliance and payment solutions for the education market, has received a strategic growth investment from the Polaris Growth Fund ("PGF").

Key Points: 
  • SEATTLE, March 5, 2020 /PRNewswire/ --TransACT Communications, LLC ("TransACT"), a leading SaaS provider of engagement, compliance and payment solutions for the education market, has received a strategic growth investment from the Polaris Growth Fund ("PGF").
  • PGF is a software-focused, specialized affiliate fund of Polaris Partners, a Boston-based private investment firm with two decades of technology investing experience.
  • Alex Jarzebowicz, Chief Executive Officer of TransACT, said, "This investment by Polaris represents a significant validation of the mission and strategy we have developed for TransACT over the last few years.
  • Headquartered in Lynnwood, Washington, TransACT Communications provides parent engagement, compliance reporting services, and payment solutions for North American K-12 and HigherEd institutions.